HealthcareServices

Plasma Protease C1-Inhibitor Market Outlook 2026–2035: Growth Drivers and Industry Forecast

March 5, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the plasma protease c1-inhibitor market from 2026–2035 with trusted insights from The Business Research Company

Across 2026–2030, what is the expected market valuation path of the Plasma Protease C1-Inhibitor Market?

The plasma protease c1-inhibitor market has experienced rapid growth in its size over recent years. It is projected to expand from $3.85 billion in 2025 to $4.4 billion in 2026, with a compound annual growth rate (CAGR) of 14.3%. The historical period’s growth can be attributed to several factors, including an increase in the diagnosis of hereditary angioedema, the availability of plasma-derived inhibitors, improvements in plasma fractionation processes, the expansion of specialty immunology clinics, and enhanced patient access to targeted therapies.

The market for plasma protease c1-inhibitor is anticipated to experience substantial expansion in the coming years. Projections indicate it will reach a value of $7.44 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 14.0%. This projected increase during the forecast period is primarily driven by factors such as the accelerated creation of advanced inhibitors, a heightened need for treatments that can be self-administered, the broadening scope of rare disease management initiatives, increased capital allocation towards recombinant biologics, and a stronger emphasis on sustained disease management. Key trends expected during this period involve the wider acceptance of recombinant c1-inhibitors, an escalating preference for plasma-derived treatments, a dedicated focus on addressing rare diseases, the broadening availability of subcutaneous delivery methods, and an amplified commitment to ensuring the safety and effectiveness of therapies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24659&type=smp

Which Drivers Are Supporting The Rise Of The Plasma Protease C1-Inhibitor Market?

The increasing financial commitment to rare diseases is anticipated to drive expansion in the plasma protease C1-inhibitor market. A rare disease refers to a medical condition impacting a small fraction of the population, typically fewer than 1 in 2,000 individuals. These conditions are frequently chronic, progressive, and can be life-threatening or disabling. The impetus for investing in rare diseases primarily stems from a growing awareness of significant unmet medical needs and the potential for substantial returns, facilitated by regulatory incentives such as orphan drug designation, market exclusivity, and reduced development costs. This investment in rare diseases stimulates the advancement of plasma protease C1-inhibitors by providing funding for research and innovation aimed at addressing hereditary angioedema and other rare conditions where C1-inhibitor deficiencies lead to severe symptoms, thereby speeding up the availability of specialized treatments. As an illustration, Global Genes, a US-based nonprofit organization, reported that in April 2024, companies developing drugs for rare diseases secured $7.1 billion in the first quarter of 2024, marking a significant 307% increase over the $1.8 billion raised during the corresponding period in 2023. Consequently, the rising investment in rare diseases is fueling the growth of the plasma protease C1-inhibitor market.

What Segments Are Identified Within The Structure Of The Plasma Protease C1-Inhibitor Market?

The plasma protease c1-inhibitor market covered in this report is segmented –

1) By Drug Class: C1-Inhibitors, C1-Esterase Inhibitor, Recombinant Inhibitor, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist

2) By Dosage Form: Lyphophlised, Injectables

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By C1-Inhibitors: Plasma-Derived C1-Inhibitor, Recombinant C1-Inhibitor

2) By C1-Esterase Inhibitor: Intravenous (IV) C1-Esterase Inhibitor, Subcutaneous (SC) C1-Esterase Inhibitor

3) By Recombinant Inhibitor: Recombinant Human C1-Inhibitor, Recombinant Analog Inhibitor

4) By Kallikrein Inhibitor: Plasma Kallikrein Inhibitor, Oral Kallikrein Inhibitor

5) By Selective Bradykinin B2 Receptor Antagonist: Injectable B2 Receptor Antagonist, Oral B2 Receptor Antagonist

What Long-Term Trends Are Expected To Shape The Future Of The Plasma Protease C1-Inhibitor Market?

Companies operating within the plasma protease C1-inhibitor market are prioritizing the creation of advanced solutions, including recombinant and plasma-derived C1-inhibitors. These innovations aim to prevent and treat hereditary angioedema (HAE) attacks, offering quicker symptom management and enhanced safety when compared to older therapies that often had limited availability or a slower onset of action. C1-inhibitors function as proteins that regulate the complement system, thereby controlling excessive bradykinin production and reducing the severity of swelling episodes linked to HAE. For example, in January 2023, Takeda Biopharmaceuticals India Private Limited, a pharmaceutical firm based in India, launched Cinryze in India, marking its initial approved C1-inhibitor therapy for hereditary angioedema. Cinryze is a plasma-derived C1-inhibitor, administered intravenously, which works by replacing deficient or dysfunctional C1-inhibitor protein to help prevent recurrent HAE attacks. Its notable attributes include high purity, demonstrated efficacy in prophylaxis, and a favorable safety profile. The therapy is applicable for long-term prophylaxis in adults and adolescents with HAE, providing benefits such as a reduced frequency and severity of angioedema attacks, an improved quality of life, and making the treatment accessible for patients in India.

Which Key Market Players Are Investing In Expansion And Innovation Within The Plasma Protease C1-Inhibitor Market?

Major companies operating in the plasma protease c1-inhibitor market are Takeda Pharmaceutical Company Limited, CSL Behring LLC, Octapharma AG, Ionis Pharmaceuticals Inc, Sanquin, Biotest AG, BioCryst Pharmaceuticals Inc, Pharming Group NV, KalVista Pharmaceuticals Inc, Pharvaris NV, Lev Pharmaceuticals, Shire Pharmaceuticals, Dyax Corp, Intellia Therapeutics Inc, Alnylam Pharmaceuticals Inc, Moderna Therapeutics Inc, Arrowhead Pharmaceuticals Inc, Protalix BioTherapeutics Inc, Apellis Pharmaceuticals Inc, Alexion Pharmaceuticals Inc, UCB SA, Pfizer Inc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/plasma-protease-c1-inhibitor-global-market-report

Which Regions Are Poised For Strategic Growth In The Plasma Protease C1-Inhibitor Market?

North America was the largest region in the plasma protease C1-inhibitor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protease c1-inhibitor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Plasma Protease C1-Inhibitor Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24659&type=smp

Browse Through More Reports Similar to the Global Plasma Protease C1-Inhibitor Market 2026, By The Business Research Company

Vascular Endothelial Growth Factor Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/vascular-endothelial-growth-factor-inhibitors-global-market-report

Checkpoint Inhibitor Market Report 2026

https://www.thebusinessresearchcompany.com/report/checkpoint-inhibitor-global-market-report

Protein Inhibitor Market Report 2026

https://www.thebusinessresearchcompany.com/report/protein-inhibitor-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795